4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results

4D Molecular Therapeutics (NASDAQ:FDMT) announced its quarterly earnings results on Thursday. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04), Zacks reports. The company had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 37.26% and a negative net margin of 182.34%.

4D Molecular Therapeutics Stock Up 2.1%

4D Molecular Therapeutics stock traded up $0.21 during midday trading on Friday, reaching $10.14. The stock had a trading volume of 832,043 shares, compared to its average volume of 698,501. 4D Molecular Therapeutics has a 52-week low of $3.00 and a 52-week high of $12.34. The firm has a market cap of $530.12 million, a price-to-earnings ratio of -3.95 and a beta of 2.77. The company has a fifty day moving average of $9.38 and a 200 day moving average of $9.49.

Institutional Trading of 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Martingale Asset Management L P raised its position in 4D Molecular Therapeutics by 12.4% in the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after purchasing an additional 1,303 shares during the period. Dimensional Fund Advisors LP raised its position in 4D Molecular Therapeutics by 3.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 58,006 shares of the company’s stock worth $504,000 after purchasing an additional 2,069 shares during the period. Russell Investments Group Ltd. raised its position in 4D Molecular Therapeutics by 11.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock worth $81,000 after purchasing an additional 2,284 shares during the period. Prelude Capital Management LLC raised its position in 4D Molecular Therapeutics by 11.1% in the 3rd quarter. Prelude Capital Management LLC now owns 23,000 shares of the company’s stock worth $200,000 after purchasing an additional 2,300 shares during the period. Finally, Wexford Capital LP purchased a new stake in 4D Molecular Therapeutics in the 3rd quarter worth about $41,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

FDMT has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Chardan Capital restated a “buy” rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Royal Bank Of Canada upped their target price on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Finally, The Goldman Sachs Group set a $33.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.88.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.